Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15334689 | 0.91 | HTR6 (0.51) | HTR6HTR2B | |
| SCHEMBL1178956 | 0.90 | HTR6 (0.64) | HTR6HTR2B | |
| SCHEMBL1178954 | 0.90 | HTR6 (0.64) | HTR6HTR2B | |
| SCHEMBL6885750 | 0.90 | HTR6 (0.64) | HTR6HTR2B | |
| SCHEMBL12872143 | 0.90 | HTR6 (0.62) | HTR6HTR2B | |
| SCHEMBL1179455 | 0.87 | HTR6 (0.48) | HTR6HTR2B | |
| SCHEMBL7996666 | 0.87 | HTR6 (0.48) | HTR6HTR2B | |
| SCHEMBL7996655 | 0.87 | HTR6 (0.54) | HTR6HTR2B | |
| SCHEMBL1179459 | 0.87 | HTR6 (0.48) | HTR6HTR2B | |
| SCHEMBL1178959 | 0.87 | HTR6 (0.54) | HTR6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610247-B1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LTD (BS) | 2016-05-25 | — | — | EP | disclosed |
| EP-2265589-B1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LTD (BS) | 2016-01-27 | — | — | EP | disclosed |
| US-9126942-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2015-09-08 | — | — | US | disclosed |
| US-9126942-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2015-09-08 | — | — | US | disclosed |
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LIMITED (BS) | 2015-02-19 | — | — | US | disclosed |
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LIMITED (BS) | 2015-02-19 | — | — | US | disclosed |
| US-8901108-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-8901108-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2014-01-09 | — | — | US | disclosed |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2014-01-09 | — | — | US | disclosed |
| US-8563723-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| US-8563723-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| EP-2610247-A1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | Abbott Healthcare Products B.V. (NL) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HOSPITALS LIMITED (BS) | 2011-02-24 | — | — | US | disclosed |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HOSPITALS LIMITED (BS) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885HTR2B 5/4885 |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885HTR2B 5/4885 |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.